EUCTR2007-004886-16-LT进行中（未招募）不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled 12-week Pilot Exploratory Study to Evaluate the Efficacy and Safety of Teikoku Tulobuterol Tape (6 mg) in Adults with Bronchial Asthma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males or females, 18 to 70 years of age.
- •2.Documented diagnosis of bronchial asthma for at least 6 month prior to visit 1.
- •3.Pre-bronchodilator FEV1 between equal or higher than 50% and equal or lower than 90% of predicted.
- •4.Improvement in FEV1 of equal or higher than 15% of predicted over pre-bronchodilator FEV1 within 20-30 minutes following inhalation of 200 mcg of salbutamol (Ventolin) from MDI with spacer at Visit 1.
- •5.Constant asthma therapy with inhaled corticosteroids for at least 4 weeks prior to Visit 1 (see chapter permitted and not permitted asthma medication).
- •6.Female subjects must be using an acceptable birth control method, postmenopausal (defined as one year without menses), physically incapable of becoming pregnant or complete abstinence from intercourse from first visit until one week following study completion. Acceptable methods of birth control include hormonal contraceptives or IUD (intrauterine device) or double barrier methods (condom or diaphragm with spermicidal agent). If practicing an acceptable method of birth control, the subject must have a negative urine pregnancy test at Visit 3.
- •7.Subject has signed and dated an informed consent form.
- •8.Subject is willing and able to comply with all study procedures, visit schedules, use of home twice daily lung function measurement (PiKo-1) and diaries.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Upper or lower respiratory tract infection during the last 4 weeks prior to Visit 1.
- •2.Asthma exacerbation during the last 4 weeks prior to Visit 1.
- •3.Asthma exacerbation requiring treatment with oral or systemic corticosteroids during the last 12 weeks prior to Visit 1.
- •4.History of life-threatening asthma at any time prior to Visit 1 defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.
- •5.Treatment with oral, systemic or depot corticosteroids during the last 12 weeks prior to Visit 1.
- •6.Any known adverse reaction including hypersensitivity to salbutamol (Ventolin) or study product or any of its constituents.
- •7.Patient is undergoing allergen desensitization therapy (SIT – specific immunotherapy).
- •8.Chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis, cystic fibrosis.
- •9.Historical or current evidence of disease which, as judged by the investigator, may put the safety of the subject at risk through study participation or may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, hepatic disease, renal disease, malignancy, hematological disease, endocrine or pulmonary disease (including, but not confined, to chronic bronchitis, bronchiectasis with no need of treatment).
- •10.Neurological or psychiatric disease which will interfere with subject’s ability to comply with study protocol requirements.
- •11.History of (within the previous 3 years) or current drug or alcohol abuse.
- •12.Female subjects who are pregnant or lactating.
- •13.Current smoker or has a smoking history more than 10 pack years.
- •14.Subject requires hospitalization or elective surgery is scheduled during the period of the study.
- •15.Subject is working at night and/or employed in shift work.
- •16.Previous enrollment in this study, currently participating or previous participation in another study during the last 30 days prior to Visit 1 (V1).
- •17.Subject is Investigator’s or sub-Investigator’s family member or is the employee of the Investigator.
- •18.Any condition that at the Investigator opinion would interfere with evaluation of the subject or may put the subject at undue risk.
研究者
相似试验
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative ColitisEUCTR2014-004559-29-Outside-EU/EEAAbbVie Inc.274
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyComparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects with Type 2 Diabetes - Post-PrandialEUCTR2007-000486-38-NLTakeda Global Research & Development Centre (Europe) Ltd.,71
进行中（未招募）
1 期
Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patientsCharcot Marie Tooth Type 1AMedDRA version: 20.0Level: LLTClassification code 10008414Term: Charcot-Marie-Tooth diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004805-30-DKPharnext SCA387
进行中（未招募）
1 期
Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patientsCharcot Marie Tooth Type 1AMedDRA version: 20.0Level: LLTClassification code 10008414Term: Charcot-Marie-Tooth diseaseSystem Organ Class: 100000004850EUCTR2020-004805-30-ITPharnext SA350
进行中（未招募）
1 期
Efficacy and Safety of BMS-986165 versus Placebo and Active Comparator in Subjects with PsoriasisEUCTR2018-001926-25-DEBristol-Myers Squibb International Corporation600